Modulation of DKK1 function through an experimental fully human anti-DKK1 antibody exhibited translational potential as a bone-anabolic agent for the treatment of human low bone mass disease, a characteristic of postmenopausal osteoporosis. The gene discussed is DKK1; the disease is postmenopausal osteoporosis.